Continuous Treatment With PREVENA Therapy for 14 Days
Study Details
Study Description
Brief Summary
The purpose of this study is to demonstrate the safety and effectiveness of Prevena Therapy for up to 14 days is comparable to the current approved use for up to 7 days. The enrolled subject will undergo 1 of 4 surgery types and be evaluated for up to 90 days.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment Group Subjects undergoing 1 of 4 types of surgery will be enrolled and treated with the PREVENA Plus Incision Management System |
Device: Prevena Plus Incision Management System with Prevena Dressings
Negative pressure pump and dressings
|
Outcome Measures
Primary Outcome Measures
- Primary Endpoint [30 Days]
The incidence of surgical site complications (SSCs), including surgical site infections (SSIs) and seromas, within 30 days (± 4 days) of the surgical procedure
Secondary Outcome Measures
- Surgical Site Complications_30 [30 Days]
The number and type of SSCs within 30 days (± 4 days) of the surgical procedure, including SSI, seroma, hematoma, dehiscence, and skin necrosis
- Surgical Site Complications_90 [90 Days]
The number and type of SSCs within 90 days (± 7 days) of the surgical procedure, including SSI, seroma, hematoma, dehiscence, and skin necrosis
- Surgical Site Infections [30 Days]
The incidence of SSI (superficial or deep) within 30 days (± 4 days) of the surgical procedure
- Seroma [30 Days]
The incidence of seroma within 30 days (± 4 days) of the surgical procedure
- Hematoma [30 Days]
The incidence of hematoma within 30 days (± 4 days) of the surgical procedure
- Dehiscence [30 Days]
The incidence of dehiscence within 30 days (± 4 days) of the surgical procedure
- Skin Necrosis [30 Days]
The incidence of skin necrosis within 30 days (± 4 days) of the surgical procedure
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subject is at least 22 years of age on the date of informed consent
-
Subject can provide informed consent
-
Subject requires a surgical procedure for 1 of the 4 specialty treatment groups (ie, lower extremity orthopedic procedure, abdominal or C-section procedure, sternotomy, or vascular procedure)
-
Subject is willing and able to return for all scheduled study visits.
-
Subject has 1 or more of the following risk factors for post-surgical complications:
-
BMI ≥ 30
-
diabetes
-
history of smoking
-
immune suppression or receiving drugs that can cause immune suppression (eg, steroids, chemotherapeutic medications, and/or antimetabolites)
-
high risk for malnutrition, as indicated by 2 or more of the following1:
-
insufficient energy intake
-
loss of muscle mass
-
loss of subcutaneous fat
-
localized or generalized fluid accumulation that may mask weight loss
-
diminished functional status as measured by hand-grip strength
-
OR -
-
has malnutrition, as determined by the investigator
-
neutropenia
-
cardiac, pulmonary, liver, or renal disease
-
history of previous surgery or radiation in the treatment area
-
Subject is pre-operatively assessed to undergo a procedure with a CDC Wound
Classification of:
-
Class I (Clean): An uninfected operative wound in which no inflammation is encountered, and the respiratory, alimentary, genital, or uninfected urinary tract is not entered
-
OR -
-
Class II (Clean Contaminated): An operative wound in which the respiratory, alimentary, genital, or uninfected urinary tract are entered under controlled conditions and without unusual contamination
-
Subject has a closed post-surgical incision for which the anticipated duration of Prevena Therapy is more than 11 days
Exclusion Criteria:
-
Subject is female and, except in the case of C-section procedures, is pregnant or lactating prior to surgery
-
Subject has signs of an infection in the surgical area or has signs of a systemic infection at the time of surgery
-
Subject is a chronic opioid user, defined per the CDC guidelines as opioid use for > 3 months, at the time of enrollment
-
Subject has any of the following:
-
condition(s) that, in the opinion of the investigator, cause the patient to be an overall health risk that is unsuitable for the surgery
-
known sensitivity to the study product components (drape and/or dressing materials in direct contact with the closed incision or skin)
-
known sensitivity to silver
-
skin cancer localized at or in proximity to the incision site
-
intraoperative issue(s) that precludes the use of Prevena Therapy
-
Subject is preoperatively assessed to undergo a procedure with a CDC Wound
Classification of:
-
Class III (Contaminated): Open, fresh, accidental wounds, and/or major breaks in sterile technique or gross spillage from the gastrointestinal tract
-
OR -
-
Class IV (Dirty-Infected): Old traumatic wounds with retained devitalized tissue and those that involve existing clinical infection or perforated viscera
-
Subject is enrolled in another interventional clinical study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sinai Hospital of Baltimore | Baltimore | Maryland | United States | 21215 |
| 2 | Minneapolis Heart Institute Foundation | Minneapolis | Minnesota | United States | 55407 |
| 3 | WakeMed Heart & Vascular | Raleigh | North Carolina | United States | 27610 |
| 4 | Oregon Health & Science University | Portland | Oregon | United States | 97239 |
| 5 | Medical University of South Carolina | Charleston | South Carolina | United States | 29425 |
Sponsors and Collaborators
- 3M
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- EM-05-014992